BioSpace News Archive

Business

Elon’s Plan B: Musk Reportedly Explores Synchron Investment

Elon Musk has reportedly gotten in touch with Synchron, a company developing a brain-computer interface (BCI) device, to explore potential investment opportunities, according to a report by Reuters.

August 23, 2022
·
2 min read
·
Tristan Manalac
Newly Developed AI could Lead to Effective Biomarker for Parkinson’s

Researchers showed they have developed artificial intelligence that may be able to detect Parkinson’s disease using nocturnal breathing signals.

August 23, 2022
·
2 min read
·
Katherine Davis
Drug Development

Novo Nordisk Combo Bests Monotherapies in Type II Diabetes Weight Loss

A combination of Novo Nordisk’s CagriSema injection for overweight people with type II diabetes resulted in a 15.6% body weight reduction compared to taking the drugs individually.

August 23, 2022
·
2 min read
·
Vanessa Doctor, RN
‘Drug Factory’ Implants Eliminate Tumors In Mice, Setting up Human Trials

Scientists found that combining cytokine drug factory implants with PD-1 protein targeting checkpoint inhibitors can eliminate advanced-stage mesothelioma tumors in mouse models.

August 23, 2022
·
2 min read
·
Vanessa Doctor, RN
Tips for Managing a Multigenerational, Post-Pandemic Workforce

While there has been a perception that young people are smarter or more creative, analyses from the Kellogg School of Management show most scientists make their breakthroughs later in life.

August 23, 2022
·
6 min read
·
Gail Dutton
Deals

Alcon Strengthens Foothold in Eye Space with $770M Aerie Buy

Alcon announced it is buying out Aerie Pharmaceuticals for about $770 million to gain access to the ophthalmic pharma firm’s open-angle glaucoma and ocular hypertension treatments.

August 23, 2022
·
2 min read
·
Tristan Manalac
Business

Novartis: Half of 1,400 Swiss Job Cuts are Leadership Positions

Of the 1,400 jobs Novartis plans to eliminate in Switzerland, about half will include leadership and management positions, the company reported Monday.

August 23, 2022
·
3 min read
·
Mark Terry
Drug Development

AskBio Subsidiary to Launch Gene Therapy Trial for Huntington’s Disease

BrainVectis will begin assessing a gene therapy for Huntington’s disease in France after receiving clearance from health authorities there to conduct a Phase I/II study.

August 23, 2022
·
2 min read
·
Alex Keown
Drug Development

Foghorn Shares Tumble After FDA Places Full Hold on Previously Scrutinized Trial

Shares of Foghorn are tumbling after the FDA placed a full clinical hold on a Phase I dose escalation study that had already been subject to a partial hold following a patient death.

August 23, 2022
·
2 min read
·
Alex Keown
Business

Report: Booster Vaccine Targeting BA.5 could be Approved Soon After Labor Day

A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.

August 23, 2022
·
4 min read
·
Mark Terry